|
| Models | Administration or technique details | Outcomes | Reference |
|
| Rats, hyperoxic | Formulation: liposome-encapsulated bovine SOD and CAT
Route: IV
Timing: before and during exposure | Increased survival rate and reduced pleural effusion in the treatment group versus saline | [44] |
|
| Rats, hyperoxic | Formulation: liposome-encapsulated bovine SOD and CAT
Route: ET
Timing: before exposure | Increased survival rate and preserved lung histology in the treatment group versus controls. | [45] |
|
| Piglets, hyperventilated and hyperoxic | Formulation: rhSOD
Route: ET
Timing: at start of exposure | Reduced neutrophils chemotactic activity, total cell count, elastase activity, and albumin in tracheal aspirates versus controls. | [46] |
|
| Rabbits, lung tissue challenged with xanthine and xanthine oxidase | Formulation: liposome-encapsulated bovine SOD and CAT
Route: ET | Preserved lung filtration coefficient in treated animals versus controls. | [47] |
|
| Transgenic mice, hyperoxic | Lung-targeted SOD3 overexpression | Reduced lung neutrophils and oxidized GSH, increased alveolar surface and lung volume density in transgenic animals versus wild-type controls. | [48] |
|
| Transgenic mice, hyperoxic | Lung-targeted SOD3 overexpression | Preserved alveolar and bronchiolar epithelium proliferation, reduced DNA damage, and preserved apical protein expression on type I cells in transgenic animals versus wild-type controls. | [49] |
|
| Rabbit, hyperoxic | Transfection with rhSOD3 containing plasmid
Route: AER | Increased lung cGMP and decreased lung NF-kB expression in transfected animals versus controls. | [50] |
|
| Transgenic mice, hyperoxic | Lung-targeted SOD3 overexpression + Antileukinate for 7 days
Route: IP | Reduced lung neutrophils, 8-isoprostane, and oxidized GSH and reduced myeloperoxidase activity in tracheal aspirates of treated transgenic animals versus treated wild type or untreated transgenic animals. | [51] |
|
